Clinical trial
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer…
NCT00158782 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00158782 |
|---|---|
| Title | Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients |
| Official title | An Open-Label, Safety, Pharmacokinetic and Pharmacodynamic Study of Multiple Doses of GW786034 and Lapatinib Concomitantly Administered in Cancer Patients |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | GW786034, lapatinib |
| Enrollment | 75 |
| Start date | Sep 28, 2004 |
| Primary completion | Aug 21, 2007 |
| Completion | Aug 21, 2007 |
| First posted | Sep 12, 2005 |
| Last update posted | Nov 17, 2017 |
| Countries | Netherlands, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: